

CITATION REPORT

List of articles citing

The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension

DOI: 10.2147/vhrm.s6392

Vascular Health and Risk Management, 2010, 6, 273-80.

Source: <https://exaly.com/paper-pdf/48686299/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
22	cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. <i>Pharmacological Reviews</i> , 2010 , 62, 525-63	22.5	677
21	Novel therapeutic strategies targeting vascular endothelium in essential hypertension. <i>Expert Opinion on Investigational Drugs</i> , 2010 , 19, 1395-412	5.9	10
20	[Tadalafil: novel aspects of phosphodiesterase-5 inhibition in the treatment of pulmonary hypertension]. <i>Archivos De Bronconeumologia</i> , 2011 , 47 Suppl 7, 26-31	0.7	
19	Treating pulmonary arterial hypertension: current treatments and future prospects. <i>Therapeutic Advances in Chronic Disease</i> , 2011 , 2, 359-70	4.9	15
18	Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions. <i>Physiological Reviews</i> , 2011 , 91, 651-90	47.9	443
17	Additive effect of tadalafil and simvastatin on monocrotaline-induced pulmonary hypertension rats. <i>Scandinavian Cardiovascular Journal</i> , 2012 , 46, 374-80	2	4
16	PDE4: a novel target in the treatment of chronic obstructive pulmonary disease. <i>Clinical Pharmacology and Therapeutics</i> , 2012 , 91, 134-42	6.1	58
15	Effects of chronic tadalafil use on the testes and sperm parameters of old albino rats. <i>Andrologia</i> , 2012 , 44 Suppl 1, 370-5	2.4	9
14	Efficacy of tadalafil in chronic hypobaric hypoxia-induced pulmonary hypertension: possible mechanisms. <i>Fundamental and Clinical Pharmacology</i> , 2013 , 27, 271-8	3.1	10
13	Tadalafil as monotherapy and in combination regimens for the treatment of pulmonary arterial hypertension. <i>Therapeutic Advances in Respiratory Disease</i> , 2013 , 7, 39-49	4.9	13
12	Pulmonary arterial hypertension related to connective tissue disease: a review. <i>Rheumatic Disease Clinics of North America</i> , 2014 , 40, 103-24	2.4	26
11	Effect of the phosphodiesterase type 5 inhibitor tadalafil on pulmonary hemodynamics in a canine model of pulmonary hypertension. <i>Veterinary Journal</i> , 2014 , 202, 334-9	2.5	8
10	Clinical and molecular genetics of the phosphodiesterases (PDEs). <i>Endocrine Reviews</i> , 2014 , 35, 195-233	27.2	157
9	Regional cerebral blood flow following single-dose and continuous-dose tadalafil after stroke. <i>Acta Neurologica Scandinavica</i> , 2014 , 130, 380-6	3.8	7
8	Quantitation of tadalafil in human plasma using a sensitive and rapid LC-MS/MS method for a bioequivalence study. <i>Journal of Pharmaceutical Analysis</i> , 2018 , 8, 271-276	14	11
7	Perioperative management with phosphodiesterase type 5 inhibitor and prostaglandin E1 for moderate portopulmonary hypertension following adult-to-adult living-donor liver transplantation: a case report. <i>Surgical Case Reports</i> , 2018 , 4, 15	0.8	1
6	Effects of masitinib compared with tadalafil for the treatment of monocrotaline-induced pulmonary arterial hypertension in rats. <i>Vascular Pharmacology</i> , 2019 , 122-123, 106599	5.9	3

5	Clinical efficacy of tadalafil compared to sildenafil in treatment of moderate to severe canine pulmonary hypertension: a pilot study. <i>Journal of Veterinary Cardiology</i> , 2019 , 24, 7-19	1.9	4
4	Bioequivalence of macitentan and tadalafil given as fixed-dose combination or single-component tablets in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2020 , 86, 2424-2434	3.8	5
3	Guanylyl Cyclase-cGMP Signaling Pathway in Melanocytes: Differential Effects of Altered Gravity in Non-Metastatic and Metastatic Cells. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	3
2	Scar-modulating agents post urethroplasty: Could phosphodiesterase-5 inhibitors be the answer?. <i>Journal of Clinical Urology</i> , 2021 , 14, 85-89	0.2	
1	Phosphodiesterase 5 (PDE5): Structure-function regulation and therapeutic applications of inhibitors. <i>Biomedicine and Pharmacotherapy</i> , 2021 , 134, 111128	7.5	15